Lonza completes acquisition of InterHealth Nutraceuticals
Acquisition aligns closely with Lonza’s speciality nutritional ingredients portfolio
Lonza has closed the acquisition of InterHealth Nutraceuticals, a leader in research, development, manufacture and marketing of proprietary, value-added nutritional ingredients for use in dietary supplements.
Based in Benicia, CA, US, the InterHealth business will become part of Lonza’s Consumer Care Business Unit, but will retain its facilities and employees. The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionising the joint-health segment.
'We are looking forward to welcoming the highly capable team to our Lonza family. They will be joining us in our quest to become the world’s leading and most-trusted supplier to the pharmaceutical, biotech and speciality ingredients markets,' said Richard Ridinger, Lonza’s Chief Executive Officer.
Lonza acquired InterHealth for a total transaction price of up to US$300m, split into an upfront payment and an earn-out payment. The transaction is expected to be immediately accretive to Lonza’s earnings.
